Perioperative Thrombotic Risk Guide for Hematology Fellows
Chokri Ben Lamine, Adult Hematology and Stem Cell Transplantation Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital & Research Center, shared a post on X:
“Perioperative Thrombotic Risk – Quick Guide for Hema Fellows
High Risk (>10%/mo VTE or >10%/yr ATE)
Recent (<3 mo) VTE
Strong thrombophilia (Protein C/S def., ATIII def., homozygous FVL/PGM, multiple thrombophilias)
APS
High-risk cancer: pancreas, brain, stomach, esophagus, myeloproliferative
AF: CHA₂DS₂-VASc ≥7, recent (<3 mo) stroke/TIA, rheumatic valve
Mechanical valve: MVR w/ major stroke RF, caged-ball/tilting-disc (any position), recent stroke/TIA
Moderate Risk (4–10%/mo VTE or 4–10%/yr ATE)
VTE within 3–12 mo
Recurrent VTE
Non-strong thrombophilia (heterozygous FVL/PGM)
Non-high-risk cancer VTE
AF: CHA₂DS₂-VASc 5–6
Mechanical valve: MVR w/o major stroke RF, bileaflet AVR w/ major stroke RF
Low Risk (<4%/mo VTE or <4%/yr ATE)
VTE >12 mo ago
AF: CHA₂DS₂-VASc 1–4
Mechanical valve: bileaflet AVR w/o major stroke RF
MCQ
Q: A 65-year-old with AF (CHA₂DS₂-VASc = 6) and VTE 8 months ago is scheduled for elective surgery. Perioperative thrombotic risk?
A) High
B) Moderate
C) Low
Answer: B) Moderate
Explanation: CHA₂DS₂-VASc = 6 → moderate AFib risk; VTE within 3–12 months → moderate VTE risk.
OSCE Scenario
Station: Pre-op anticoagulation planning for high-risk VTE
Prompt: 55-year-old with recent (<3 mo) DVT on warfarin, elective colectomy scheduled.
Tasks:
Identify thrombotic risk category (High)
Discuss bridging anticoagulation plan with LMWH
Outline timing for last LMWH dose before surgery and restart post-op
Counsel on bleeding vs thrombosis risk
Key points for examiner:
Recognize high risk → needs bridging
Stop warfarin 5 days pre-op
Last therapeutic LMWH 24 h pre-op
Credits to ASH SAP 9th edition ”
Stay updated with Hemostasis Today.
-
Aug 14, 2025, 23:47World Thrombosis Day: Know your Risk in DVT
-
Aug 14, 2025, 12:52JAMA Review: Immune Thrombotic Thrombocytopenic Purpura (iTTP)
-
Aug 14, 2025, 12:33Louise Bannon: The World Thrombosis Day Campaign is Calling on Industry Leaders
-
Aug 14, 2025, 10:58Thomas Reiser: Why October 13 Marks World Thrombosis Day?
-
Aug 14, 2025, 04:03Perioperative Thrombotic Risk Guide for Hematology Fellows
-
Aug 14, 2025, 23:47Health-related Quality of Life in Children with von Willebrand Disease
-
Aug 14, 2025, 17:54Omid Seidizadeh: From Genotype and Phenotype! Variability in Type 2 von Willebrand Disease
-
Aug 14, 2025, 17:36Samin Mohsenian: Thrombotic Paradox in Congenital Fibrinogen Deficiencies
-
Aug 14, 2025, 17:10Emmanuel J Favaloro: DOACs and Mechanical Coagulation Test Systems
-
Aug 14, 2025, 13:09Thrombin Generation Assay to Guide Factor Therapy With Fitusiran
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman
-
Aug 13, 2025, 10:25Joshua Muia on His HTRS Leadership Role Impact
-
Aug 11, 2025, 05:16Andreas Calatzis: Any Information on Soviet Thrombelastographs?
-
Aug 9, 2025, 15:36NBCA: Blood Clot Survivor Runs 2025 NYC Marathon with Team Stop the Clot